Executive Director, Medical Affairs - Lexicon Pharmaceuticals
Talia Biran is a global medical affairs leader with 20 years of diverse experience in the pharmaceutical industry, having worked in companies such as Novartis, Merck and Janssen, with particular expertise in oncology, infectious disease and endocrinology. Talia contributed to the development, approval and launch of several drugs, including Abiraterone Acetate (Zytiga ®, prostate cancer), Letrozole (Femara®, breast cancer), and Octreotide (Sandostatin LAR®, neuroendocrine tumors (NETs) and acromegaly). Talia Biran is an Executive Director, Medical Affairs for Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing breakthrough treatments for human disease including diabetes, carcinoid syndrome and other indications. In that role, she is leading medical affairs while collaborating closely with clinical development and marketing. Talia holds a master’s of science (M.Sc) in microbiology from Tel-Aviv University, Department of Life Sciences, Tel-Aviv, Israel. Her thesis, under the supervision of Professor Sara Lavi, focused on Gene Amplification of SV-40 and its link to tumorogeneis.